Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
TretamineF1 I SEP / 98
TretinoinF1 Vitamin A acid I SEP / 98
Tretinoin and its salts and derivativesF1 I SEP / 98
Triamcinolone acetonide

in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays

II JAN / 15
Triamcinolone acetonide.

in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays

III JAN / 15
Triamterene and its saltsF1 I SEP / 98
Triazolam and its saltsTS I SEP / 98
Tricaine and its saltsF1 I SEP / 98
Triethanolamine oleate III SEP / 98
Triethanolamine salicylate in concentrations greater than 20% III SEP / 98
Triethanolamine salicylate. in concentrations up to and including 20% U
Trifluoperazine and its saltsF1 I SEP / 98
Triflupromazine and its saltsF1 I SEP / 98
TrifluridinePDL I DEC / 13
Trihexyphenidyl and its saltsF1 I SEP / 98
Triiodothyropropionic acidF1 I SEP / 98
TrilostaneF1 I SEP / 98
Trimebutine and its saltsF1 I SEP / 98
TrimeperidineN I JUN / 02
Trimeprazine and its saltsF2 I SEP / 98
TrimethadioneF1 I SEP / 98
Trimethaphan camsylateF1 I SEP / 98
Trimethoprim and its saltsF1 I SEP / 98
Trimetrexate and its saltsF1 I SEP / 98
Trimipramine and its saltsF1 I SEP / 98
TrioxsalenF1 I SEP / 98
Tripelennamine and its salts III SEP / 98
Triprolidine III SEP / 98
TroglitazoneF1 I SEP / 98
Tropicamide and its saltsF1 in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada I SEP / 98
Trospium chlorideF1 I OCT / 07
Trovafloxacin or its salts or derivativesPDL

including but not limited to alatrofloxacin

I DEC / 13
Trypsin U DEC / 98
Tryptophan (L-Tryptophan)F1

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

I DEC / 11
Tubocurarine and its salts I SEP / 98
Tubocurarine chlorideF1 I SEP / 98
TybamateF1 I SEP / 98
Tylosin or its saltsPDL

for veterinary use, when sold for the treatment of chronic colitis in dogs

I DEC / 14
Tylosin or its salts or derivativesPDL

for human use, including but not limited to tildipirosin, tilmicosin

I DEC / 14
Typhoid vaccines/Salmonella Typhi vaccines I FEB / 02
Tyrothricine III SEP / 98
Ubiquinone U DEC / 98
Umeclidinium or its salts or derivativesPDL I FEB / 14
Uracil and its saltsF1 when sold for the treatment of cancer I DEC / 11
Urea in topical preparations in concentrations of more than 25% II SEP / 98
UrokinasePDL I DEC / 13
Ursodeoxycholic acid and its saltsF1 I SEP / 98
UstekinumabF1 I MAR / 11
Vaccines (except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) I FEB / 02
Vaccines. which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus II FEB / 02
Valaciclovir and its saltsF1 I SEP / 98
Valdecoxib and its saltsF1 I MAY / 04
Valganciclovir and its salts and derivativesF1 I MAY / 04
Valproic acid and its saltsF1 I SEP / 98
Valrubicin and its derivativesF1 I DEC / 02
Valsartan and its salts and derivativesF1 I SEP / 99
Vancomycin and its salts and derivativesF1 I SEP / 98
Vardenafil and its saltsF1 I APR / 07
Varenicline or its saltsPDL I DEC / 13
Varicella Zoster immune globulin I FEB / 02
Varicella vaccine (chicken pox) I FEB / 02
Vasopressin and its saltsF1 I SEP / 98
Vecuronium bromideF1 I SEP / 98
Vedaprofen and its salts and derivativesF1 I MAY / 00
VedolizumabPDL I MAR / 15
Vegetable tar except shampoos in concentrations of 5% or less III SEP / 98
Velaglucerase alfaPDL I DEC / 13
VelpatasvirPDL I AUG / 16
Venetoclax or its saltsPDL I NOV / 16
Venlafaxine and its saltsF1 I SEP / 98
Verapamil and its saltsF1 I SEP / 98
Veratrum album and its alkaloids and their saltsF2 I SEP / 98
Veratrum viride and its alkaloids and their saltsF2 I SEP / 98
Vernakalant or its saltsPDL I APR / 17
VidarabineF1 I SEP / 98
Vigabatrin and its salts and derivativesF1 I SEP / 98
Vilazodone or its saltsPDL I AUG / 15
VinbarbitalC2 I JUN / 02
Vinblastine and its saltsF1 I SEP / 98
Vincristine and its saltsF1 I SEP / 98
Vindesine and its saltsF1 I SEP / 98
Vinorelbine and its saltsF1 I SEP / 98
VinylbitalC2 I JUN / 02
Viomycin and its salts and derivativesF1 I SEP / 98
Virginiamycin and its salts and derivativesF2 I SEP / 98
Vitamin APDL

in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A

I DEC / 13
Vitamin B12 with Intrinsic Factor ConcentrateF1 I SEP / 98
Vitamin DPDL

in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by the person of more than 1,000 International Units of Vitamin D

I DEC / 13
Vitamin KF2 except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less I OCT / 05
Vitamins any parenterals not otherwise included in Schedule I II SEP / 98
Vitamins in injectable form for parenteral nutrition I JAN / 03
Vorapaxar or its saltsPDL I AUG / 16
VoriconazoleF1 I FEB / 07
VorinostatF1 I MAR / 11
Vortioxetine or its saltsPDL

including but not limited to vortioxetine hydrobromide

I DEC / 14
Voxilaprevir or its saltsPDL I SEP / 17
Xanthinol nicotinateF1 I SEP / 98
Xylazine and its saltsF1 I SEP / 98
Xylometazoline and it salts in nasal preparations for pediatric use (0.05%) II SEP / 98
Xylometazoline and its salts in nasal preparations for adults (0.1%) U

1920 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled